Rubicon Research (NSE:RUBICON) Other Current Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:RUBICON Rubicon Research Ltd NSE:RUBICON
19 GF Score
Price ₹1,828.80
! 5 Warning Signs
View Full Analysis

What is Rubicon Research Other Current Liabilities?

Rubicon Research NSE:RUBICON +0.36% 19 Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Rubicon Research's other current liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Rubicon Research's quarterly other current liabilities increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹2,705 Mil) but then declined from Mar. 2026 (₹2,705 Mil) to Jun. 2026 (₹0 Mil).

Rubicon Research's annual other current liabilities increased from Mar. 2024 (₹553 Mil) to Mar. 2025 (₹1,375 Mil) and increased from Mar. 2025 (₹1,375 Mil) to Mar. 2026 (₹2,705 Mil).

Rubicon Research Other Current Liabilities Related Terms

Rubicon Research Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Rubicon Research's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rubicon Research Other Current Liabilities Chart

Rubicon Research Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
146.35 552.63 1,374.79 2,705.23

Rubicon Research Quarterly Data
Mar23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only 1,374.79 1,524.87 0.00 2,705.23 0.00
NSE:RUBICON
19GF Score
Rubicon Research Ltd NSE:RUBICON
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rubicon Research Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹0 Mil mean?
Rubicon Research (NSE:RUBICON) has a Other Current Liabilities of ₹0 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Rubicon Research.
Is Rubicon Research's Other Current Liabilities too high?
Rubicon Research's current Other Current Liabilities is ₹0 Mil. Overall, Rubicon Research has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Other Current Liabilities compare to LLY and JNJ?
Rubicon Research's Other Current Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Rubicon Research. Rubicon Research's current Other Current Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Other Current Liabilities of ₹0 Mil. The current Other Current Liabilities is ₹0 Mil. Rubicon Research's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rubicon Research Business Description

Other Exchanges 544578:India
Address Road No. 33, MedOne House, B-75, Wagle Estate, Thane West, Thane, MH, IND, 400 604
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
19GF Score

Get the complete analysis for NSE:RUBICON

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,828.80
Price